PTHS — Pelthos Therapeutics Share News
0.000.00%
Last trade - 00:00- $65.08m
- $125.20m
- $16.80m
Brief: Pelthos Therapeutics Financial Statements Should No Longer Be Relied Upon For Quarter Ended March 31- SEC Filing
Pelthos Therapeutics Q2 revenue rises on Zelsuvmi adoption
Brief: Pelthos Therapeutics Announces CFO Transition
Brief: Pelthos Therapeutics Announces First Patient Dosed In Phase 1B/2A Clinical Trial Of Ct2000 In Eye Pain
Brief: Pelthos Therapeutics Announces Fourth Quarter And Full Year 2025 Financial Results
Brief: Pelthos Therapeutics Inc - To Offer Securities Up To $200 Million
Brief: Pelthos Therapeutics Acquires Xeglyze® Topical Treatment For Head Lice
Brief: Pelthos Therapeutics - On Dec 23, Enters Asset Purchase Agreement With Hatchtech - SEC Filing
Brief: Pelthos Therapeutics Expands Board Of Directors With The Appointment Of Andrew Einhorn
Brief: Pelthos Therapeutics Signs Major Pharmacy Benefit Manager Agreement
Brief: Pelthos Therapeutics Inc Files For Offering Of Up To 8.14 Million Common Shares By The Selling Stockholders
Brief: Channel Therapeutics Announces Reverse Stock Split as Merger with Pelthos Closes and $50.1M Private Placement Completes